Clearside Biomedical (CLSD) announced that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024. Dr. Chong is a board-certified retinal specialist with more than 25 years of experience as a retinal physician and navigating all phases of ophthalmic drug development. Dr. Chong served most recently as VP, Global Head of Retina DAS at Johnson & Johnson (JNJ) Innovative Medicine.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CLSD:
- Navigating a Regulatory Maze: Clearside Biomedical’s Challenge with Global Compliance and Anti-Corruption Laws
- Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- These 2 ‘Strong Buy’ Penny Stocks Could Surge Over 200%, Say Analysts
- Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
- Clearside Biomedical Announces Registered Direct Offering Pricing
